<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>6462776</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">30991620</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">6462776</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">S2213-1582(19)30162-7</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1016/j.nicl.2019.101812</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">101812</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical variables, mean (standard deviation).</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0005"><label>Table 1</label><caption><p>Demographic and clinical variables, mean (standard deviation).</p></caption><alt-text id="al0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>HC (N = 31)</th><th>AD (N = 29)</th><th>DLB (N = 31)</th><th>Between-group differences</th></tr></thead><tbody><tr><td>Male: female</td><td>22:9</td><td>20:9</td><td>19:12</td><td>χ<sup>2</sup> = 0.73, p = 0.70<xref rid="tf0005" ref-type="table-fn">a</xref></td></tr><tr><td>Study 1: study 2</td><td>15:16</td><td>13:16</td><td>12:19</td><td>χ<sup>2</sup> = 0.60, p = 0.74<xref rid="tf0005" ref-type="table-fn">a</xref></td></tr><tr><td>Age</td><td>76.4 (7.2)</td><td>75.2 (8.6)</td><td>78.1 (6.7)</td><td>F<sub>2,88</sub> = 1.16, p = 0.32<xref rid="tf0010" ref-type="table-fn">b</xref></td></tr><tr><td>AChEI</td><td>–</td><td>26</td><td>28</td><td>χ<sup>2</sup> = 0.007, p = 0.93<xref rid="tf0015" ref-type="table-fn">c</xref></td></tr><tr><td>PD meds</td><td>–</td><td>1</td><td>18</td><td>χ<sup>2</sup> = 20.66, p &lt; 0.001<xref rid="tf0015" ref-type="table-fn">c</xref></td></tr><tr><td>Duration</td><td>–</td><td>3.7 (1.7)<xref rid="tf0030" ref-type="table-fn">f</xref></td><td>3.4 (2.3)</td><td>U = 339, p = 0.14<xref rid="tf0020" ref-type="table-fn">d</xref></td></tr><tr><td>MMSE</td><td>28.9 (1.1)</td><td>21.8 (3.8)</td><td>22.0 (4.3)</td><td>t<sub>58</sub> = 0.20, p = 0.85<xref rid="tf0025" ref-type="table-fn">e</xref></td></tr><tr><td>CAMCOG</td><td>96.7 (3.2)</td><td>70.3 (13.5)</td><td>73.3 (13.6)</td><td>t<sub>58</sub> = 0.86, p = 0.39<xref rid="tf0025" ref-type="table-fn">e</xref></td></tr><tr><td>UPDRS III</td><td>1.94 (2.8)</td><td>3.5 (4.0)</td><td>18.1 (10.0)</td><td>t<sub>58</sub> = 7.32, p &lt; 0.001<xref rid="tf0025" ref-type="table-fn">e</xref></td></tr><tr><td>CAF total</td><td>–</td><td>1.00 (2.5)<xref rid="tf0030" ref-type="table-fn">f</xref></td><td>4.8 (4.9)<xref rid="tf0035" ref-type="table-fn">g</xref></td><td>t<sub>56</sub> = 3.66, p = 0.001<xref rid="tf0025" ref-type="table-fn">e</xref></td></tr><tr><td>NPI total</td><td>–</td><td>5.9 (5.5)<xref rid="tf0040" ref-type="table-fn">h</xref></td><td>14.6 (11.0)<xref rid="tf0045" ref-type="table-fn">i</xref></td><td>t<sub>54</sub> = 3.68, p = 0.001<xref rid="tf0025" ref-type="table-fn">e</xref></td></tr><tr><td>NPI hall</td><td>–</td><td>0<xref rid="tf0050" ref-type="table-fn">j</xref></td><td>1.6 (1.8)<xref rid="tf0045" ref-type="table-fn">i</xref></td><td>t<sub>53</sub> = 4.53, p &lt; 0.001<xref rid="tf0025" ref-type="table-fn">e</xref></td></tr></tbody></table><table-wrap-foot><fn><p>AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer's disease; CAF total, Clinical Assessment of Fluctuations total score; CAMCOG, Cambridge Cognitive Examination; DLB, Dementia with Lewy bodies; Duration, duration of cognitive symptoms in years; HC, healthy controls; Mayo total, Mayo Fluctuations Scale; MMSE, Mini Mental State Examination; PD meds, number of patients taking dopaminergic medication for the management of Parkinson's disease symptoms; UPDRS III, Unified Parkinson's Disease Rating Scale III (motor subsection); NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0005"><label>a</label><p id="np0005">Chi-square test HC, AD, DLB.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0010"><label>b</label><p id="np0010">One-way ANOVA HC, AD, DLB.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0015"><label>c</label><p id="np0015">Chi-square test AD, DLB.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0020"><label>d</label><p id="np0020">Mann Whitney <italic>U</italic> test AD, DLB.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0025"><label>e</label><p id="np0025">Student's <italic>t</italic>-test AD, DLB.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0030"><label>f</label><p id="np0030">N = 28.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0035"><label>g</label><p id="np0035">N = 30.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0040"><label>h</label><p id="np0040">N = 27.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0045"><label>i</label><p id="np0045">N = 29.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0050"><label>j</label><p id="np0050">N = 26.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical variables, mean (standard deviation).</div>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>HC (N = 31)</th><th>AD (N = 29)</th><th>DLB (N = 31)</th><th>Between-group differences</th></tr></thead><tbody><tr><td>Male: female</td><td>22:9</td><td>20:9</td><td>19:12</td><td>χ2 = 0.73, p = 0.70???</td></tr><tr><td>Study 1: study 2</td><td>15:16</td><td>13:16</td><td>12:19</td><td>χ2 = 0.60, p = 0.74???</td></tr><tr><td>Age</td><td>76.4 (7.2)</td><td>75.2 (8.6)</td><td>78.1 (6.7)</td><td>F2,88 = 1.16, p = 0.32???</td></tr><tr><td>AChEI</td><td>–</td><td>26</td><td>28</td><td>χ2 = 0.007, p = 0.93???</td></tr><tr><td>PD meds</td><td>–</td><td>1</td><td>18</td><td>χ2 = 20.66, p &lt; 0.001???</td></tr><tr><td>Duration</td><td>–</td><td>3.7 (1.7)???</td><td>3.4 (2.3)</td><td>U = 339, p = 0.14???</td></tr><tr><td>MMSE</td><td>28.9 (1.1)</td><td>21.8 (3.8)</td><td>22.0 (4.3)</td><td>t58 = 0.20, p = 0.85???</td></tr><tr><td>CAMCOG</td><td>96.7 (3.2)</td><td>70.3 (13.5)</td><td>73.3 (13.6)</td><td>t58 = 0.86, p = 0.39???</td></tr><tr><td>UPDRS III</td><td>1.94 (2.8)</td><td>3.5 (4.0)</td><td>18.1 (10.0)</td><td>t58 = 7.32, p &lt; 0.001???</td></tr><tr><td>CAF total</td><td>–</td><td>1.00 (2.5)???</td><td>4.8 (4.9)???</td><td>t56 = 3.66, p = 0.001???</td></tr><tr><td>NPI total</td><td>–</td><td>5.9 (5.5)???</td><td>14.6 (11.0)???</td><td>t54 = 3.68, p = 0.001???</td></tr><tr><td>NPI hall</td><td>–</td><td>0???</td><td>1.6 (1.8)???</td><td>t53 = 4.53, p &lt; 0.001???</td></tr></tbody></table></div>AChEI, number of patients taking acetylcholinesterase inhibitors; AD, Alzheimer's disease; CAF total, Clinical Assessment of Fluctuations total score; CAMCOG, Cambridge Cognitive Examination; DLB, Dementia with Lewy bodies; Duration, duration of cognitive symptoms in years; HC, healthy controls; Mayo total, Mayo Fluctuations Scale; MMSE, Mini Mental State Examination; PD meds, number of patients taking dopaminergic medication for the management of Parkinson's disease symptoms; UPDRS III, Unified Parkinson's Disease Rating Scale III (motor subsection); NPI, Neuropsychiatric Inventory; NPI hall, NPI hallucination subscore.aChi-square test HC, AD, DLB.bOne-way ANOVA HC, AD, DLB.cChi-square test AD, DLB.dMann Whitney U test AD, DLB.eStudent's t-test AD, DLB.fN = 28.gN = 30.hN = 27.iN = 29.jN = 26.</transformed-table></extracted-table></extracted-tables-set>